Traitement des neuropathies dysimmunitaires chroniques: impact du réseau des Centres des maladies rares en Italie

Translated title of the contribution: Treatment of chronic immune-mediated neuropathies: Impact of the rare diseases centers network in Italy

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Chronic immune-mediated neuropathies represent a heterogeneous group of mostly demyelinating neuropathies thought to be caused by an autoimmune response to peripheral nerve antigens. They include chronic infl ammatory demyelinating polyradiculoneuropathy (CIDP) and related variants, multifocal motor neuropathy (MMN) and neuropathy associated with an IgM monoclonal gammopathy with antibody activity against myelin-associated glycoprotein (MAG). Most of these neuropathies respond to immune therapy even though their response to therapy may be different, thereby confi rming that their distinct characteristics have relevant clinical implications. While clinicians and scientists are intrigued by the desire to better clarify the cause and pathogenesis of these disorders, the need to allow affected patients to be reimbursed by insurance companies or the national health system can lead to the risk of lumping all these neuropathies under the umbrella term of CIDP to facilitate patientsaccess to costly therapies.

Original languageFrench
JournalRevue Neurologique
Volume169
Issue numberSUPPL.1
DOIs
Publication statusPublished - 2013

Fingerprint

Rare Diseases
Polyradiculoneuropathy
Italy
Myelin-Associated Glycoprotein
Paraproteinemias
Insurance
Autoimmunity
Peripheral Nerves
Immunoglobulin M
Therapeutics
Antigens
Antibodies
Health

Keywords

  • CIDP
  • IgM monoclonal gammopathy
  • Immunoglobulin therapy
  • MAG
  • Multifocal motor neuropathy
  • Neuropathy
  • Paraproteinemic neuropathy
  • Steroids

ASJC Scopus subject areas

  • Clinical Neurology
  • Neurology

Cite this

@article{89f37e253e6c4c338d3674c28ea8f9bd,
title = "Traitement des neuropathies dysimmunitaires chroniques: impact du r{\'e}seau des Centres des maladies rares en Italie",
abstract = "Chronic immune-mediated neuropathies represent a heterogeneous group of mostly demyelinating neuropathies thought to be caused by an autoimmune response to peripheral nerve antigens. They include chronic infl ammatory demyelinating polyradiculoneuropathy (CIDP) and related variants, multifocal motor neuropathy (MMN) and neuropathy associated with an IgM monoclonal gammopathy with antibody activity against myelin-associated glycoprotein (MAG). Most of these neuropathies respond to immune therapy even though their response to therapy may be different, thereby confi rming that their distinct characteristics have relevant clinical implications. While clinicians and scientists are intrigued by the desire to better clarify the cause and pathogenesis of these disorders, the need to allow affected patients to be reimbursed by insurance companies or the national health system can lead to the risk of lumping all these neuropathies under the umbrella term of CIDP to facilitate patientsaccess to costly therapies.",
keywords = "CIDP, IgM monoclonal gammopathy, Immunoglobulin therapy, MAG, Multifocal motor neuropathy, Neuropathy, Paraproteinemic neuropathy, Steroids",
author = "E. Nobile-Orazio",
year = "2013",
doi = "10.1016/S0035-3787(13)70058-4",
language = "Francese",
volume = "169",
journal = "Revue Neurologique",
issn = "0035-3787",
publisher = "Elsevier Masson",
number = "SUPPL.1",

}

TY - JOUR

T1 - Traitement des neuropathies dysimmunitaires chroniques

T2 - impact du réseau des Centres des maladies rares en Italie

AU - Nobile-Orazio, E.

PY - 2013

Y1 - 2013

N2 - Chronic immune-mediated neuropathies represent a heterogeneous group of mostly demyelinating neuropathies thought to be caused by an autoimmune response to peripheral nerve antigens. They include chronic infl ammatory demyelinating polyradiculoneuropathy (CIDP) and related variants, multifocal motor neuropathy (MMN) and neuropathy associated with an IgM monoclonal gammopathy with antibody activity against myelin-associated glycoprotein (MAG). Most of these neuropathies respond to immune therapy even though their response to therapy may be different, thereby confi rming that their distinct characteristics have relevant clinical implications. While clinicians and scientists are intrigued by the desire to better clarify the cause and pathogenesis of these disorders, the need to allow affected patients to be reimbursed by insurance companies or the national health system can lead to the risk of lumping all these neuropathies under the umbrella term of CIDP to facilitate patientsaccess to costly therapies.

AB - Chronic immune-mediated neuropathies represent a heterogeneous group of mostly demyelinating neuropathies thought to be caused by an autoimmune response to peripheral nerve antigens. They include chronic infl ammatory demyelinating polyradiculoneuropathy (CIDP) and related variants, multifocal motor neuropathy (MMN) and neuropathy associated with an IgM monoclonal gammopathy with antibody activity against myelin-associated glycoprotein (MAG). Most of these neuropathies respond to immune therapy even though their response to therapy may be different, thereby confi rming that their distinct characteristics have relevant clinical implications. While clinicians and scientists are intrigued by the desire to better clarify the cause and pathogenesis of these disorders, the need to allow affected patients to be reimbursed by insurance companies or the national health system can lead to the risk of lumping all these neuropathies under the umbrella term of CIDP to facilitate patientsaccess to costly therapies.

KW - CIDP

KW - IgM monoclonal gammopathy

KW - Immunoglobulin therapy

KW - MAG

KW - Multifocal motor neuropathy

KW - Neuropathy

KW - Paraproteinemic neuropathy

KW - Steroids

UR - http://www.scopus.com/inward/record.url?scp=84875633693&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84875633693&partnerID=8YFLogxK

U2 - 10.1016/S0035-3787(13)70058-4

DO - 10.1016/S0035-3787(13)70058-4

M3 - Articolo

C2 - 23452770

AN - SCOPUS:84875633693

VL - 169

JO - Revue Neurologique

JF - Revue Neurologique

SN - 0035-3787

IS - SUPPL.1

ER -